Aldeyra Therapeu (ALDX) Stock Price, Quote & News

Company Profile

Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated and metabolic diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator th...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 761 4904

Fax: 339 674 6495

Website: www.aldeyra.com

Address:

131 Hartwell Avenue, Suite 320, Lexington, United States

alperne Sep. 1 at 1:29 PM

$ALDX TRT kardes 😃

0 · Reply

Milanfinest Sep. 1 at 9:31 AM

$ALDX

0 · Reply

PeterV9764 Aug. 31 at 12:51 AM

$ALDX Abbvie is printing money as fast as they can! The below bodes well for Aldx! AbbVie and REGENXBIO executed an amendment to the collaboration and license agreement established between the two companies on September 10, 2021. The amendment includes an updated milestone structure for the DR program, under the terms of which AbbVie will pay REGENXBIO $100 million upon first subject dosed in the Phase IIb/III trial and an additional $100 million upon first subject dosed in a second Phase III clinical trial. REGENXBIO will pay for all costs for Phase IIb of the Phase IIb/III trial.

2 · Reply

Moneymachineuser Aug. 30 at 8:48 PM

$ALDX if I recall correct, but there was a $12.** sell order in the order book - level 2 few days ago. Good Luck To Everyone Here!🐉

1 · Reply

MontanaT Aug. 29 at 10:40 PM

$ALDX 6.2 AH

1 · Reply

Smellmahass Aug. 29 at 7:19 PM

$ALDX 3rd time try. Got to be approved this time right?

1 · Reply

Milanfinest Aug. 29 at 5:48 PM

$ALDX

0 · Reply

Bigbas Aug. 29 at 3:42 PM

$ALDX yeeeeeaaaaahhhhh buddy!!

0 · Reply

oochiegoochie Aug. 29 at 3:10 PM

$ALDX

0 · Reply

Milanfinest Aug. 29 at 1:59 PM

$ALDX

1 · Reply

Aldeyra Therapeutics Receives Orphan Designation from the European Medicines Agency for ADX-2191 for the Treatment of Primary Large B-Cell Lymphomas of Immune-Privileged Sites, including Primary Vitreoretinal Lymphoma

Aug 19, 2025, 7:01 AM EDT - 13 days ago

Aldeyra Therapeutics Receives Fast Track Designation for ADX‑2191 for the Treatment of Retinitis Pigmentosa

Aug 6, 2025, 7:01 AM EDT - 26 days ago

Aldeyra Therapeutics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Jul 24, 2025, 7:00 AM EDT - 5 weeks ago

Aldeyra Therapeutics Receives Orphan Designation from the European Medicines Agency for ADX-2191 for the Treatment of Inherited Retinal Dystrophies including Retinitis Pigmentosa

Jul 17, 2025, 7:00 AM EDT - 6 weeks ago

Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease

Jul 2, 2025, 9:23 PM EDT - 2 months ago

Aldeyra Therapeutics: Pivotal FDA Decision After Reproxalap's Chamber Data

Jun 26, 2025, 7:00 AM EDT - 2 months ago

Aldeyra Therapeutics Receives Special Protocol Assessment Agreement Letter from the U.S. Food and Drug Administration for ADX-2191 for the Treatment of Primary Vitreoretinal Lymphoma

Jun 17, 2025, 7:00 AM EDT - 2 months ago

Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease

May 29, 2025, 7:01 AM EDT - 3 months ago

Aldeyra Therapeutics to Participate in the 2025 Jefferies Global Healthcare Conference

May 7, 2025, 4:07 PM EDT - 4 months ago

ALDX INVESTIGATION NOTICE: Aldeyra Therapeutics, Inc. Investors are Notified of the Pending Securities Investigation; Contact BFA Law

May 7, 2025, 8:46 AM EDT - 4 months ago

ALDX SECURITIES UPDATE: Aldeyra Therapeutics Investors with Losses may have been affected by Securities Violations – Contact BFA Law (NASDAQ:ALDX)

May 6, 2025, 4:42 PM EDT - 4 months ago

Aldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After Stock Drops 70% On FDA's Reproxalap Complete Response Letter – Hagens Berman

May 6, 2025, 3:48 PM EDT - 4 months ago

ALDX SECURITIES NEWS: Aldeyra Therapeutics, Inc. Investigation Could Allow Investors to Recover Losses; Contact BFA Law to Discuss

May 5, 2025, 6:34 PM EDT - 4 months ago

Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Chamber Trial of Reproxalap and Plans NDA Resubmission

May 5, 2025, 4:00 PM EDT - 4 months ago

Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Topline Results from Phase 3 Dry Eye Disease Clinical Trials of Reproxalap

May 5, 2025, 3:38 PM EDT - 4 months ago

ALDX SECURITIES NOTICE: Suffer Losses on Aldeyra Therapeutics, Inc.? Investors are Alerted to Contact BFA Law about its Continuing Investigation

May 3, 2025, 7:18 AM EDT - 4 months ago

ALDX INQUIRY NOTICE: Aldeyra Therapeutics (NASDAQ:ALDX) Investors may have been affected by Securities Violations -- Contact BFA Law

May 1, 2025, 8:08 AM EDT - 4 months ago

ALDX INVESTIGATION: Aldeyra Therapeutics (NASDAQ:ALDX) Investors with Losses are Urged to Contact BFA Law about its Investigation into the Company

Apr 30, 2025, 3:38 PM EDT - 4 months ago

ALDX ANNOUNCEMENT: Aldeyra Therapeutics, Inc. Investors may have been affected by Securities Violations - Contact BFA Law

Apr 29, 2025, 4:07 PM EDT - 4 months ago

ALDX NEWS: Aldeyra Therapeutics, Inc. is Being Investigated for Securities Violations - Investors are Alerted to Contact BFA Law

Apr 29, 2025, 9:49 AM EDT - 4 months ago

ALDX Investors Have Opportunity to Join Aldeyra Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

Apr 28, 2025, 9:00 PM EDT - 4 months ago

Bragar Eagel & Squire, P.C. Is Investigating TechTarget and Aldeyra and Encourages Investors to Contact the Firm

TTGT

Apr 28, 2025, 3:46 PM EDT - 4 months ago

ALDX NOTICE: Aldeyra Therapeutics, Inc. Investors are Notified of Pending Securities Investigation - Contact BFA Law if You Lost Money

Apr 27, 2025, 8:20 AM EDT - 4 months ago

ALDX SHAREHOLDER REVIEW: Aldeyra Therapeutics (NASDAQ:ALDX) is being Investigated after 75% Stock Drop – Investors are Urged to Contact BFA Law

Apr 25, 2025, 3:22 PM EDT - 4 months ago

ALDX SHAREHOLDER NEWS: Aldeyra Therapeutics, Inc. 75% Stock Plummet Leads to Securities Investigation - Investors are Urged to Contact BFA Law

Apr 25, 2025, 7:36 AM EDT - 4 months ago

ALDX SHAREHOLDERS: Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) 75% Stock Drop Triggers Investigation – Contact BFA Law if You Lost Money

Apr 24, 2025, 3:18 PM EDT - 4 months ago

ALDX NOTICE: A Securities Investigation was initiated on behalf of Aldeyra Therapeutics, Inc. Investors - Contact BFA Law

Apr 23, 2025, 3:36 PM EDT - 4 months ago

ALDX INVESTIGATION: Aldeyra Therapeutics, Inc. is being Investigated for Securities Violations - Investors are Notified to Contact BFA Law

Apr 23, 2025, 8:18 AM EDT - 4 months ago

LEGAL NOTICE: Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Investors are Notified of the Pending Securities Investigation - Contact BFA Law

Apr 22, 2025, 3:23 PM EDT - 4 months ago

ALDX LEGAL NEWS: BFA Law Announces that Aldeyra Therapeutics, Inc. is being Investigated - Contact the Firm if You Lost Money

Apr 21, 2025, 10:52 AM EDT - 4 months ago

Aldeyra Therapeutics: A Mispriced Gem With Reproxalap's CRL Creating A Golden Buying Opportunity

Apr 21, 2025, 8:33 AM EDT - 4 months ago

ALDX LEGAL REMINDER: Did Aldeyra Therapeutics, Inc. Commit Securities Violations? Contact BFA Law (NASDAQ:ALDX)

Apr 18, 2025, 10:00 AM EDT - 4 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aldeyra Therapeutics, Inc. (ALDX) and Encourages Shareholders to Learn More About the Investigation

Apr 17, 2025, 10:00 AM EDT - 4 months ago

Aldeyra Therapeutics, Inc. (ALDX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Apr 17, 2025, 8:36 AM EDT - 4 months ago

ALDX INVESTOR INVESTIGATION: Aldeyra Therapeutics, Inc. Investors are Reminded of the Ongoing Securities Investigation – Contact BFA Law (NASDAQ:ALDX)

Apr 17, 2025, 7:00 AM EDT - 4 months ago

Aldeyra Therapeutics Appoints Chip Clark to Board of Directors

Apr 16, 2025, 4:07 PM EDT - 4 months ago

ALDX INVESTIGATION REMINDER: Aldeyra Therapeutics, Inc. Investors are Reminded of the Pending Investigation -- Contact BFA Law

Apr 16, 2025, 10:00 AM EDT - 4 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Aldeyra Therapeutics, Inc. (ALDX) Shareholders to Inquire about Securities Investigation

Apr 15, 2025, 3:36 PM EDT - 4 months ago

ALDX INVESTIGATION: The Aldeyra Therapeutics, Inc. Securities Investigation is Ongoing - Contact BFA Law if You Suffered Losses

Apr 15, 2025, 10:00 AM EDT - 4 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Aldeyra Therapeutics, Inc. (ALDX) And Encourages Shareholders to Connect

Apr 15, 2025, 8:18 AM EDT - 4 months ago

ALDX INVESTIGATION NOTICE: Suffer Losses on Aldeyra Therapeutics, Inc.? Contact BFA Law about the Securities Investigation (NASDAQ:ALDX)

alperne Sep. 1 at 1:29 PM

$ALDX TRT kardes 😃

0 · Reply

Milanfinest Sep. 1 at 9:31 AM

$ALDX

0 · Reply

PeterV9764 Aug. 31 at 12:51 AM

2 · Reply

Moneymachineuser Aug. 30 at 8:48 PM

$ALDX if I recall correct, but there was a $12.** sell order in the order book - level 2 few days ago. Good Luck To Everyone Here!🐉

1 · Reply

MontanaT Aug. 29 at 10:40 PM

$ALDX 6.2 AH

1 · Reply

Smellmahass Aug. 29 at 7:19 PM

$ALDX 3rd time try. Got to be approved this time right?

1 · Reply

Milanfinest Aug. 29 at 5:48 PM

$ALDX

0 · Reply

Bigbas Aug. 29 at 3:42 PM

$ALDX yeeeeeaaaaahhhhh buddy!!

0 · Reply

oochiegoochie Aug. 29 at 3:10 PM

$ALDX

0 · Reply

Milanfinest Aug. 29 at 1:59 PM

$ALDX

1 · Reply

Moneymachineuser Aug. 29 at 2:36 AM

$ALDX what a beautiful story Aldeyra is becoming after both crl's

0 · Reply

MontanaT Aug. 28 at 10:12 PM

$ALDX @StockBraker you didnt sell did you? touched $6.18 today lol

1 · Reply

johnnygogogo Aug. 28 at 6:06 PM

$ALDX I bet Todd secretly hates Reproxalap. Kidding but my point is he’s a discovery guy wanting to make other discoveries and Reprox has had the most convoluted, labyrinthine path. I’ve said this before but nice to see more progress on something that’s not called Reproxalap. That’s the goal right now while we wait for bureaucracy and ABBV has a decision to make.

1 · Reply

TheGodsMustBeCrazy Aug. 28 at 5:28 PM

$ALDX

0 · Reply

Aidsg Aug. 28 at 5:03 PM

$ALDX man, how wrong I was, this things keeps proving itself time after time

1 · Reply

MontanaT Aug. 28 at 4:48 PM

$ALDX

0 · Reply

MontanaT Aug. 28 at 4:38 PM

$ALDX Hang tight, something’s on the way ;)

1 · Reply

MontanaT Aug. 28 at 4:31 PM

$ALDX

1 · Reply

All4Retiring Aug. 28 at 4:30 PM

$ALDX

0 · Reply

Moneymachineuser Aug. 28 at 2:36 PM

$ALDX 650 more shares added :)

1 · Reply

BilboBagginses Aug. 28 at 2:24 PM

$ALDX thanking past me for loading more at $3, the gift that keeps giving

2 · Reply

RoyBasch Aug. 28 at 2:20 PM

$ALDX has never been in a stronger position. The PDUFA decision is set for Dec 16 – the FDA already reviewed the study that was submitted and considered it sufficient for filing, even deciding the second trial was not needed to be submitted. That’s a clear signal this time approval is within reach. On top of that, ADX-2191 now carries Orphan Drug Designation in both the US and EU for two different indications. Regulatory tailwinds, market exclusivity, and a de-risked path ahead – Aldeyra’s setup has never looked better. ⸻ 👉 Soll ich dir noch eine kurze, aggressive Variante im „Warren Buffett-Stil“ machen, die mehr wie ein „Strong conviction call“ klingt?

2 · Reply

Market Cap	349.79M
Revenue (ttm)	0.00
Net Income (ttm)	-55.85M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.27

Volume	453,300
Avg Vol	1,075,666
Day's Range	N/A - N/A
Shares Out	59.90M
Stochastic %K	60%
Beta	0.80
Analysts	Strong Sell
Price Target	$8.80